Articles tagged with Molecular Targets
The study revealed a comprehensive functional network of 10,525 genes constructed using supervised machine learning that integrates protein datasets and RNA sequencing data from 11 cancer types. The approach identified protein modules and a hierarchical modular organization linked to cancer hallmarks and clinical characteristics.
Researchers at St. Jude Children's Research Hospital have developed a novel solution to analyze the vast amounts of data generated by synthesizing large collections of new molecules. By using fragmentation patterns as universal barcodes, they can remove a key bottleneck in small molecule synthesis and screening.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
Researchers have developed a new generation of cell-penetrating antibodies that can target cancer cells and deliver therapeutic molecules directly into tumor cells. The 3E10 antibody shows great promise for treating cancers with defective DNA repair pathways.
Researchers discovered that Prostaglandin E2 drives skin cells to age and enables some of these cells to become pre-cancerous, leading to increased cancer risk. The study found that blocking PGE2 reduced the chances of aged cells becoming precancerous.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
Researchers have identified new potential therapeutic targets for diabetic kidney disease (DKD), a leading cause of kidney failure. The study reveals common and cell-type-specific changes caused by insulin-resistance, representing new targets for pharmacological or targeted gene therapy approaches.
Insilico Medicine has nominated ISM8969, an orally available NLRP3 inhibitor, as a potential treatment for various inflammatory diseases. The compound has shown promising results in preclinical evaluation studies, including balanced druggability and efficacy against inflammation.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
Dr. Christopher Seet has received a $2.9 million R37 MERIT Award from the National Cancer Institute to develop innovative T cell therapies for cancer. The grant will support research into iPSC-derived T cells, which can be engineered for enhanced tumor-fighting capabilities.
Researchers have developed a network-based approach to understand how immune cells called microglia transform and drive harmful processes like neuroinflammation in Alzheimer's disease. The study identified three unique subtypes of harmful microglia that promote disease progression, with genetic signatures driving their behaviors.
Three Texas A&M biologists have received NIH Maximizing Investigators’ Research Awards to support their research on type IV pili, darter fish social behaviors and bacteriophages. Drs Koch, Moran and Ramsey will explore bacterial behavior, genetic mechanisms and neural basis of paternal care in fish.
Researchers at Texas A&M University developed a non-toxic pesticide using neem seed extract and nanotechnology. The new formulation shows improved targeting ability and reduces environmental pollution by up to 80-90% of sprayed pesticides missing their target entirely.
Scientists at UCSF have developed engineered T cells that act as immune referees to soothe overreacting immune responses and mope up inflammatory molecules. These cells could improve treatment for organ transplants, type 1 diabetes and other autoimmune conditions by reducing the need for harsh immunosuppressant drugs.
Scientists have created a living cell therapy that can navigate to specific organs using a
Researchers at UCSF found a brain signature of resilience in mice that suggests a new way to treat severe depression. Stress changes activity in the amygdala, distinguishing resilient from less resilient mice. By stimulating neurons, the team improved decision-making and reduced ruminating in less resilient mice.
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
Researchers identified five fungi species with toxic effects against the bacterium, which disrupts cellular levels of thiols essential for bacterial survival. The findings support a strategy for developing treatment-shortening drugs by targeting biological processes maintaining thiol levels.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
Research highlights Nup93's critical role in endothelial cell function and vascular health, with promising findings for new treatments to slow down aging. Low Nup93 levels are associated with inflammation and cellular aging, while restoring its levels can reverse harmful effects.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
Researchers found neurotransmitters GABA and choline in the venom of estuarine and reef stonefish, which can modulate cardiovascular function. The discovery could aid in targeted treatments and venom-derived compound development for drug discovery.
Researchers found that genetic collisions between transcription and DNA replication lead to large tandem duplications in cancer cells, which can be identified through dosage imbalance. These duplicates are associated with poor patient survival and high correlation with mutations in genes TP53, CDK12, and SPOP.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers at University of California - San Francisco designed biological sensors that can ensure engineered cells are activated in tumor environments, making cancer therapies more effective. The new sensors, called SNIPRs, can bind to soluble molecules and alter gene expression, offering a promising approach for targeted therapies.
A new scientific statement highlights improvements in diagnosis, initial treatment, and long-term management of patients with Kawasaki Disease, emphasizing the need for tailored management strategies. Advances in cardiac imaging techniques and risk categorization have led to better patient outcomes.
A new real-world study found that Comprehensive Genomic Profiling (CGP) leads to better personalized treatment and patient outcomes when done early in a cancer diagnosis. CGP-assessed patients received biomarker-driven targeted therapy or immunotherapy, significantly improving overall survival of 25 months compared to chemotherapy alone.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
Researchers from Brazil's Center for Research on Redox Processes in Biomedicine found that high blood sugar can cause thrombosis by altering endothelial function and promoting platelet adhesion. They identified a specific molecular mechanism involving protein disulfide isomerase A1 as a key regulator of this process.
A new study by MUSC researchers reveals how cancer cells develop resistance to hydroxychloroquine, an anti-malarial drug repurposed for cancer therapy. The findings suggest that targeting specific metabolic and export pathways can prevent resistance, opening the door for novel combination therapies.
A recent study has identified 51 amyotrophic lateral sclerosis (ALS)-associated mutations in mitochondrial DNA that could help diagnose the disease. The mutations, which include 13 that increase the risk of ALS and 38 protective ones, were found to be significantly associated with an increased or decreased risk of developing the disease.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
The collaboration utilized Insilico's generative biology AI platform, Pharma.AI, to identify a novel lead for treating oncology diseases. The joint R&D team addressed the druggability challenge of highly novel targets using novel scaffolds generated by Chemistry42.
Researchers discovered that tumor dormancy in breast cancer can be triggered by specific signaling changes within small cell clusters, called tumor emboli. Key mechanisms include reduced activity of mTOR and structural shifts in E-cadherin, which are regulated by the PI3K pathway.
Researchers have identified 44 genetic regions associated with metabolite levels in the body, which can influence cardiovascular risk. The study found a potential molecular mechanism by which six genetic loci are linked to cardiovascular risk through the metabolites they regulate.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers developed an in vitro model of murine peritoneal macrophage aging to study molecular mechanisms and develop innovative strategies. Chronic treatment with CB3 completely prevented the increase of p21CIP1 and maintained proliferative activity in day 14 macrophages.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
Researchers at MedUni Vienna identified a potential way forward for targeted therapies that do not rely on antibiotics. The study focused on the restriction-modification system of Borrelia bacteria and discovered its importance in protecting the bacteria against foreign DNA.
Researchers at Nagoya University have identified a chemical compound that regulates stomatal density in plants, reducing water loss through transpiration. The compound, Stomidazolone, inhibits stomatal development without affecting plant growth, offering a promising solution for drought-prone environments.
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
Researchers at Weill Cornell Medicine identified a unique enzyme called FTSJ1 that enables melanoma cells to escape oxidative stress and spread. By targeting this enzyme, therapies may prevent or treat metastasis with minimal side effects.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers developed an efficient analysis method to precisely determine gamma-glutamyl dipeptide concentrations, enabling prediction of full-bodied cheese flavor development. The method uses ultra-high performance liquid chromatography-mass spectrometry and can analyze 60 cheese samples per day.
A clinical study published in Clinical Cancer Research confirmed that tissue stiffening in HER2-negative breast cancer can directly cause disease progression and metastasis. The use of the MeCo Score diagnostic tool was found to predict the likelihood of relapse or recurrence among patients with early-stage breast cancer.
Researchers humanize the lupus-derived autoantibody 3E10, preserving its therapeutic efficacy, to create novel cell-penetrating antibodies targeting tumors and RAD51. Humanized variants exhibit faster cell uptake and superior in vivo tumor targeting.
Researchers at U of T have discovered that C2H2 zinc finger proteins, which primarily bind to DNA, also regulate RNA processing through various mechanisms. These proteins modify mRNA, controlling its length and altering it after transcription.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
A new study found that fibroblast growth factor 21 (FGF21) is an independent predictor of all-cause mortality in older adults. The Polsenior2 study revealed that middle and high FGF21 levels were associated with increased mortality risk, particularly when adjusted for age, co-morbidities, and blood parameters.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.